Login / Signup

Pharmacokinetics and safety of brivaracetam in neonates with repeated electroencephalographic seizures: A multicenter, open-label, single-arm study.

Ronit M PresslerGeraldine BoylanEugene DempseyKerstin Alexandra KlotzWalter KrauwinkelEdgar WillDiego MoritaFlorin FloricelJan-Peer ElshoffJohn van den Anker
Published in: Epilepsia open (2023)
BRV plasma concentrations in neonates were consistent with data in older children receiving BRV oral solution, and with data from adults receiving a nominal IV dose of 25 mg twice daily. BRV was well-tolerated, with no drug-related TEAEs reported.
Keyphrases
  • open label
  • electronic health record
  • physical activity
  • big data
  • low birth weight
  • young adults
  • emergency department
  • middle aged
  • data analysis
  • cross sectional
  • community dwelling
  • phase ii study
  • phase ii
  • adverse drug